Prochlorperazine IM Dosing for a 14-Year-Old, 44 kg Patient
For a 14-year-old boy weighing 44 kg, the appropriate IM dose of prochlorperazine for severe nausea and vomiting is 2.64 mg (calculated as 0.06 mg/kg × 44 kg), administered as a deep intramuscular injection into the upper outer quadrant of the buttock.
Dosing Rationale
The FDA-approved dosing for prochlorperazine in pediatric patients is weight-based at 0.06 mg of drug per pound (0.132 mg/kg) of body weight for severe nausea and vomiting 1. Converting this patient's weight:
- 44 kg = 97 pounds
- 97 pounds × 0.06 mg/lb = 5.82 mg per dose
Alternatively using the metric conversion:
- 44 kg × 0.132 mg/kg = 5.8 mg per dose
Control is usually obtained with one dose, and the duration of activity following IM administration may last up to 12 hours 1.
Critical Safety Considerations
Age and Weight Restrictions
- Prochlorperazine should not be used in pediatric patients under 20 pounds in weight or two years of age 1
- This 44 kg (97 lb) patient meets the minimum weight requirement
Extrapyramidal Symptoms (EPS) Risk
Children are significantly more prone to develop extrapyramidal reactions, even on moderate doses 1. The systematic review by 2 found EPS occurred in 9% (95% CI 3-29) of children receiving single doses and 4% (95% CI 1-11) with multiple doses. Therefore:
- Use the lowest effective dosage
- Do not exceed the prescribed dose
- Monitor closely for restlessness, muscle spasms, or dystonic reactions
- Have diphenhydramine available for EPS management (as suggested by combination therapy in 3)
Contraindications and Precautions
- DO NOT USE in pediatric surgery 1
- Take particular precaution in children with acute illnesses or dehydration 1
- If the patient reacts with signs of restlessness and excitement, do not administer additional doses 1
Administration Technique
- Inject deeply into the upper, outer quadrant of the buttock 1
- Subcutaneous administration is not advisable due to local irritation 1
- Do not mix with other agents in the syringe 1
Monitoring Requirements
After administration, monitor for:
- Sedation (reported in 10% of children in multiple-dose studies) 2
- Extrapyramidal symptoms including akathisia, dystonia, muscle spasms
- Hypotension (though more common with IV administration) 4
- Therapeutic response to nausea/vomiting
Alternative Considerations
If this is for breakthrough nausea/vomiting rather than initial treatment, consider that:
- Prochlorperazine 5-10 mg is listed as breakthrough therapy in adult guidelines 5, 6
- For pediatric agitation/psychiatric indications, the dose would be the same 0.06 mg/kg calculation 3, 1
Repeat Dosing
If necessary, subsequent doses may be given by the same route, though control is usually obtained with one dose 1. The duration of activity is up to 12 hours, so reassess before considering repeat administration.
Important caveat: While the FDA label provides clear weight-based dosing, the safety profile in children warrants conservative use, close monitoring, and readiness to manage EPS with anticholinergic agents if needed.